GLP-1s in the Hospital: Should We Hold, Continue, or Start Inpatient?

A patient is scheduled for surgery tomorrow morning. During medication reconciliation, you notice they took their weekly semaglutide dose two days ago. They feel fine, but anesthesia is concerned about aspiration risk. Meanwhile, glucose levels are creeping up. Do you hold the medication, continue it, or change course entirely?

Situations like this are becoming routine as GLP-1 receptor agonists move from outpatient specialty drugs to everyday therapies. As more hospitalized patients arrive on semaglutide, liraglutide, dulaglutide, and similar agents, clinicians are increasingly asked to make real-time decisions about how GLP-1 therapy should be managed during surgery or acute illness.

This article reviews current evidence and expert consensus on managing GLP-1 therapy in hospitalized patients. It highlights common risks such as nausea, ileus, and diabetic ketoacidosis while offering simple, practical protocols for inpatient teams.

Table of Contents

Growing use of GLP-1s in hospitalized patients
Risks that influence inpatient decisions
When to hold GLP-1 therapy in the hospital
When to continue or restart GLP-1s
Starting GLP-1s during hospitalization
Practical protocols for surgery and acute illness
FAQs

Growing Use of GLP-1s in Hospitalized Patients

GLP-1 receptor agonists are now widely prescribed for glycemic control, weight loss, and cardiovascular risk reduction. Consequently, inpatient clinicians increasingly encounter patients admitted while taking these medications. However, most pivotal GLP-1 trials excluded acutely ill or surgical patients, leaving important gaps in inpatient guidance.

Despite limited randomized data, professional societies have begun addressing hospital-based GLP-1 use in perioperative and medical settings. Clinicians must balance long-term metabolic benefits against short-term safety concerns. Therefore, a structured and consistent approach is essential to avoid unnecessary harm or uncontrolled hyperglycemia.

Risks That Influence GLP-1 Use in the Inpatient Setting

Several clinical risks drive decisions about whether to hold or continue GLP-1 therapy during hospitalization. One major concern is delayed gastric emptying, a known pharmacologic effect of GLP-1 receptor agonists. In surgical patients, this can increase aspiration risk during anesthesia, particularly when fasting status is uncertain.

Gastrointestinal side effects also play a significant role. Nausea, vomiting, and early satiety may worsen dehydration or limit oral intake during acute illness. On the other hand, continuing therapy in a patient who is eating reliably and remains asymptomatic may be reasonable.

There is also concern about diabetic ketoacidosis, especially when insulin doses are reduced too aggressively. Although GLP-1 agents do not directly cause DKA, they may mask rising glucose levels in insulin-deficient patients. For this reason, careful glucose and ketone monitoring remains essential in higher-risk individuals.

When to Hold GLP-1 Therapy in the Hospital

Holding GLP-1 therapy is often appropriate in certain hospitalized patients, particularly during acute illness or surgery. Patients who are NPO, experiencing persistent nausea or vomiting, or undergoing major procedures generally benefit from pausing therapy.

For elective surgery, many experts recommend holding daily GLP-1 agents on the day of the procedure. Weekly formulations are commonly withheld for one week prior to surgery. While recommendations vary, consistency within institutional inpatient diabetes protocols helps reduce confusion and medication errors.

During acute medical admissions, overall clinical stability should guide decision-making. If oral intake is unreliable or hemodynamic instability is present, holding GLP-1 therapy is prudent. In these situations, insulin-based regimens provide more predictable and controllable glucose management.

When to Continue or Restart GLP-1s

Not all hospitalized patients require discontinuation of GLP-1 therapy. Stable medical admissions who are eating normally, have minimal gastrointestinal symptoms, and are not undergoing procedures may safely continue treatment.

Restarting therapy after a temporary hold is generally safe once oral intake resumes and symptoms resolve. Clinicians should consider whether dose re-titration is appropriate, particularly if several doses were missed. Restarting at a lower dose may help reduce nausea and improve tolerance.

Discharge planning is critical. Patients should receive clear instructions on when and how to resume their home GLP-1 regimen. Referral to outpatient follow-up or digital care platforms such as Healthcare.pro can help support continuity after hospitalization.

Starting GLP-1s During Hospitalization

Initiating GLP-1 therapy during hospitalization remains controversial. Although inpatient stays may appear to offer an opportunity to optimize long-term diabetes care, acute illness is rarely the ideal time to start a medication associated with gastrointestinal side effects.

That said, select patients admitted for non-acute reasons may be appropriate candidates. For example, a patient hospitalized for diagnostic evaluation rather than severe illness may benefit from initiation shortly before discharge. In these cases, patient education and clear outpatient follow-up plans are essential.

Overall, most experts recommend deferring initiation until after discharge. This approach allows for gradual dose escalation and closer monitoring in the outpatient setting, improving tolerability and adherence.

Practical Protocols for Surgery and Acute Illness

Simple protocols can improve how GLP-1 medications are managed across hospital services. For elective surgery, daily agents are typically held on the day of surgery, while weekly formulations are held one week prior. Blood glucose can be managed with basal-bolus insulin when needed.

For acute medical admissions, clinicians should assess oral intake, gastrointestinal symptoms, and overall stability. If intake is poor, GLP-1 therapy should be held and insulin used for glycemic control. Once the patient stabilizes and resumes eating, therapy can be restarted.

Clear documentation is essential. Orders should specify whether GLP-1 therapy is intentionally held and when reassessment should occur. Discharge education helps prevent unintentional long-term discontinuation.

Conclusion

Managing GLP-1 therapy in hospitalized patients requires thoughtful, individualized decision-making. While these medications offer meaningful outpatient benefits, inpatient care demands caution. Holding therapy during surgery or acute illness is often appropriate, while continuation may be reasonable in stable patients. In most cases, initiation is best deferred until after discharge.

FAQs

Should GLP-1s always be stopped during hospitalization?
No. Stable patients who are eating and not undergoing procedures may safely continue therapy based on clinical judgment.

How long before surgery should GLP-1s be held?
Daily agents are often held on the day of surgery, while weekly agents are typically held for one week prior.

Can GLP-1s cause diabetic ketoacidosis?
They do not directly cause DKA, but inadequate insulin in insulin-deficient patients may increase risk.

Is it safe to restart GLP-1s at discharge?
Yes, once oral intake is reliable. Some patients may require dose re-titration if therapy was held for an extended period.

Should GLP-1s be started in the hospital?
In most cases, initiation is better handled in the outpatient setting to allow gradual dose escalation and monitoring.

This content is not medical advice. For any health issues, always consult a healthcare professional. In an emergency, call 911 or your local emergency services.